Novel Biomarker MicroRNAs for Subtyping of Acute Coronary Syndrome: A Bioinformatics Approach

Zhu, Yujie; Lin, Yuxin; Yan, Wenying; Sun, Zhandong; Jiang, Zhi Hong; Shen, Bairong; Jiang, Xiaoqian; Shi, Jingjing

doi:10.1155/2016/4618323

Cited by 17 publications

(19 citation statements)

References 86 publications

(91 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Su et al (35) demonstrated that upregulating hsa-mir-142-3p could ameliorate myocardial ischemic injury. of note, hsa-mir-142-3p is considered to be a biomarker for acute Mi (36). in the present study, it was found that hsa-mir-142-3p was downregulated in the blood of patients with Mi.…”

Section: Discussionsupporting

confidence: 59%

Uncovering potential differentially expressed miRNAs and targeted mRNAs in myocardial infarction based on integrating analysis

Wang¹,

Cao²

2020

Mol Med Rep

View full text Add to dashboard Cite

Myocardial infarction (Mi) is one of the leading causes of death globally. The aim of the present study was to find valuable micrornas (mirnas/mirs) and target mrnas in order to contribute to our understanding of the pathology of Mi. mirna and mrna data were downloaded for differential expression analysis. Then, a regulatory network between mirnas and mrnas was established, followed by function annotation of target mrnas. Thirdly, prognosis and diagnostic analysis of differentially methylated target mrnas were performed. Finally, an in vitro experiment was used to validate the expression of selected mirnas and target mrnas. a total of 19 differentially expressed mirnas and 1,007 differentially expressed mRNAs were identified. Several regulatory interaction pairs between mirna and mrnas were identified, such as hsa-mir-142-2p-long-chain-fattyacid-coa ligase 1 (acSl1), hsa-mir-15a-3p-nicotinamide phosphoribosyltransferase (naMPT), hsa-mir-33b-5p-regulator of G-protein signaling 2 (rGS2), hsa-mir-17-3p-Jun dimerization protein 2 (JdP2), hsa-mir-24-1-5p-aquaporin-9 (aQP9) and hsa-mir-34a-5p-STaT1/aKT3. of note, it was demonstrated that acSl1, naMPT, rGS2, JdP2, aQP9, STaT1 and aKT3 had diagnostic and prognostic values for patients with Mi. in addition, STaT1 was involved in the 'chemokine signaling pathway' and 'Jak-STaT signaling pathway'. aKT3 was involved in both the 'MaPK signaling pathway' and 'T cell receptor signaling pathway'. reverse transcription-quantitative Pcr validation of hsa-mir-142-3p, hsa-mir-15a-3p, hsa-mir-33b-5p, acSl1, naMPT, rGS2 and JdP2 expression was consistent with the bioinformatics analysis. In conclusion, the identified miRNAs and mRNAs may be involved in the pathology of Mi.

show abstract

Section: Discussionsupporting

confidence: 59%

Uncovering potential differentially expressed miRNAs and targeted mRNAs in myocardial infarction based on integrating analysis

Wang¹,

Cao²

2020

Mol Med Rep

View full text Add to dashboard Cite

show abstract

“…Four groups of miRNAs are identified, which are involved in regulation of the CV system of which nearly 18 seem specific for AMI, for example miR-155, miR-34a, miR-126, miR-133a, miR-208b, and a few others show much promise as specific and accurate markers of dysfunction. 23…”

Section: Micrornas (Mirnas)mentioning

confidence: 99%

Cardiac Biomarkers: What Is and What Can Be

Jacob

Khan

2018

Ind J Car Dis Wom

View full text Add to dashboard Cite

Cardiac biomarkers are of great importance in the timely, accurate diagnosis and management of acute coronary syndrome as well as the prognosis. Diagnosis in the golden period is of utmost importance to institute therapy at the earliest and possibly reverse the myocardial damage. Cardiac biomarkers are also a powerful tool for triaging. Among the many biomarkers, the earliest examined were the myocardial enzymes, several myocardial proteins, peptides, and many other molecules. The latest addition to the repertoire is the microRNAs, which are stable molecules detectable in circulation. About four groups are found to be involved in regulation of circulatory system, and some show promise as specific and early markers of acute coronary syndrome and cardiac dysfunction. As in other fields of medicine, personalized precise treatment may be possible with the use of microRNAs. However, as of now, a multipronged approach, involving different markers of which troponins are necessary, seems to be the best way forward.

show abstract

“…[16][17] It is also predicted that microRNA changes such as up-regulation or down-regulation occur at much earlier stages of disease development, while the accurate diagnosis of MI is a target for prognosis and treatment of patients. [18][19] In the current study, the predictive value of circulating microRNAs, including microRNA-1 and microRNA-221-3p, as informative markers for MI, was determined in 200 patients on their presentation to the emergency ward of a cardiovascular medical center using a 300-μl of whole blood sample. Both of the tested microRNAs significantly increased in patients with MI, even in cases whose symptoms were manifested within 1-12 hours or the ones with initially negative CTnI.…”

Section: Discussionmentioning

confidence: 99%

“…Due to its high sensitivity and specificity, it is proposed to use microRNA-221-3p as a biomarker to detect MI in patients with primary PCI in order to reduce mortality in the affected patients. 18,25 A c c e p t e d…”

Section: Discussionmentioning

confidence: 99%

Up-Regulation of Cell-Free MicroRNA-1 and MicroRNA-221-3p Levels in Patients with Myocardial Infarction Undergoing Coronary Angiography

Mansouri

Mohammadzad

2020

Adv Pharm Bull

View full text Add to dashboard Cite

Purpose: Myocardial infarction (MI), known as a multifactorial disease, remains the predominant cause of mortality and sudden deaths annually. The current study aimed to measure the expression of microRNA-1 and microRNA-221-3p in MI patients. Methods: In the current study, 100 healthy controls (with no history of heart disease) and 200 patients with MI were selected. Patients were divided into two groups based on angiography results: normal (no significant artery stenosis) and primary percutaneous coronary intervention (primary PCI, significant artery stenosis). The levels of microRNA-1 and microRNA-221-3p were quantified using real-time quantitative polymerase chain reaction. The correlation between levels of microRNAs and the common cardiac markers were analyzed statistically. Results: In comparison to fold change, microRNA-1 elevations were 8.5-fold in normal patients and 60-fold in patients with primary PCI; while microRNA-221-3p levels were 210- fold higher in primary PCI and 31.31-fold higher in normal cases compared with the healthy controls. Receiver operating characteristic analysis showed that the area under the curve (AUC) for circulating microRNA-1 and microRNA-221 were 0.903 and 0.958 in normal patients and 0.927 and 0.985 in primary PCI patients (p <0.0001), respectively. Pearson correlation (ρ) analysis showed that circulation of microRNA-1 correlated with serum levels of cardiac troponin I (CTnI) (ρ=0.24), creatinine (ρ =0.34), creatinine kinase-myocardial band (CK-MB) (ρ=0.31), and microRNA-221-3p was significantly correlated with serum levels of CTnI (ρ =0.6), creatinine (ρ=0.41), and CK-MB (ρ=0.37), (P <0.0001). Conclusion: The study underscored the potential of microRNA-1 and microRNA-221-3p as informative biomarkers and positively correlated with artery stenosis in MI.

show abstract

Novel Biomarker MicroRNAs for Subtyping of Acute Coronary Syndrome: A Bioinformatics Approach

Cited by 17 publications

References 86 publications

Uncovering potential differentially expressed miRNAs and targeted mRNAs in myocardial infarction based on integrating analysis

Uncovering potential differentially expressed miRNAs and targeted mRNAs in myocardial infarction based on integrating analysis

Cardiac Biomarkers: What Is and What Can Be

Up-Regulation of Cell-Free MicroRNA-1 and MicroRNA-221-3p Levels in Patients with Myocardial Infarction Undergoing Coronary Angiography

Contact Info

Product

Resources

About